On March 5, 2024 Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, taking place in San Diego on April 5-10 (Press release, Bicycle Therapeutics, MAR 5, 2024, View Source [SID1234640770]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: Bicycle Toxin Conjugates for the treatment of solid tumors
Session Title: Cancer Treatment: New Technologies
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5807
Speaker/Lead Author: Stephen Walsh, Ph.D., Bicycle Therapeutics
Title: Modulation of the natural killer cell immune response to tumor with a synthetic tumor-immune cell agonist, NK-TICA
Session Title: CAR-NK, NK Engagers and NK Modulators
Date and Time: Monday, April 8, at 9 a.m. PT/12 p.m. ET
Abstract Number: 1340
Speaker/Lead Author: Fay Dufort, Ph.D., Bicycle Therapeutics
Title: Tumor-targeted activation of CD137 using Bicycles: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2-expressing cancers
Session Title: Immune Modulation Employing Agonist or Co-Stimulatory Approaches
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5301
Speaker/Lead Author: Johanna Lahdenranta, Ph.D., Bicycle Therapeutics
The posters will be made available in the Publications section of bicycletherapeutics.com following the presentations.